Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

hameln pharma pty ltd - oxycodone hydrochloride, quantity: 50 mg - injection, solution - excipient ingredients: citric acid monohydrate; hydrochloric acid; sodium citrate dihydrate; water for injections; sodium hydroxide; sodium chloride - oxycodone-hameln solution for injection or infusion is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

hameln pharma pty ltd - oxycodone hydrochloride, quantity: 10 mg - injection, solution - excipient ingredients: sodium citrate dihydrate; sodium hydroxide; sodium chloride; hydrochloric acid; water for injections; citric acid monohydrate - oxycodone-hameln solution for injection or infusion is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

hameln pharma pty ltd - oxycodone hydrochloride, quantity: 20 mg - injection, solution - excipient ingredients: citric acid monohydrate; sodium chloride; hydrochloric acid; sodium citrate dihydrate; water for injections; sodium hydroxide - oxycodone-hameln solution for injection or infusion is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - follitropin delta, quantity: 72 microgram - injection, solution - excipient ingredients: phenol; methionine; sodium sulfate decahydrate; dibasic sodium phosphate dodecahydrate; polysorbate 20; phosphoric acid; sodium hydroxide; water for injections - controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (art) such as an in vitro fertilisation (ivf) or intracytoplasmic sperm injection (icsi) cycle.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - follitropin delta, quantity: 36 microgram - injection, solution - excipient ingredients: phenol; methionine; sodium sulfate decahydrate; dibasic sodium phosphate dodecahydrate; polysorbate 20; phosphoric acid; sodium hydroxide; water for injections - controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (art) such as an in vitro fertilisation (ivf) or intracytoplasmic sperm injection (icsi) cycle.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - follitropin delta, quantity: 12 microgram - injection, solution - excipient ingredients: phenol; methionine; sodium sulfate decahydrate; dibasic sodium phosphate dodecahydrate; polysorbate 20; phosphoric acid; sodium hydroxide; water for injections - controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (art) such as an in vitro fertilisation (ivf) or intracytoplasmic sperm injection (icsi) cycle.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - secukinumab, quantity: 150 mg/ml - injection, solution - excipient ingredients: trehalose dihydrate; water for injections; methionine; nitrogen; polysorbate 80; histidine hydrochloride monohydrate - plaque psoriasis,cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy.,psoriatic arthritis,cosentyx is indicated for the treatment of adult patients with active psoriatic arthritis including axial manifestations of psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug (dmard) therapy has been inadequate.,axial spondyloarthritis (axspa) with or without radiographic damage,ankylosing spondylitis (axspa with radiographic damage),cosentyx is indicated for the treatment of adult patients with active ankylosing spondylitis.,non-radiographic axial spondyloarthritis (axspa without radiographic damage),cosentyx is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axspa) with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or mri change, who have had an inadequate response to, or are intolerant to, nsaids.,juvenile idiopathic arthritis (jia),enthesitis-related arthritis (era),cosentyx is indicated for the treatment of active enthesitis-related arthritis in patients 4 years and older who have had an inadequate response or were intolerant to at least one nsaid and at least one dmard.,juvenile psoriatic arthritis (jpsa),cosentyx is indicated for the treatment of active juvenile psoriatic arthritis in patients 2 years and older who have had an inadequate response or were intolerant to at least one nsaid and at least one dmard.,hidradenitis suppurativa (hs),cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult patients with an inadequate response to conventional systemic hidradenitis suppurativa therapy.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - oxycodone hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium citrate dihydrate; sodium chloride; sodium hydroxide; citric acid monohydrate; water for injections; hydrochloric acid - oxynorm solution for injection or infusion is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

base) for anaphylaxis 1mg/1ml (1 in 1,000) solution for injection pre-filled syringes (martindale pharmaceuticals ltd - adrenaline - solution for injection - 1mg/1ml

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - insulin glargine, quantity: 32.74 mg - injection, solution - excipient ingredients: metacresol; zinc chloride; glycerol; sodium hydroxide; hydrochloric acid; water for injections - treatment of diabetes mellitus in adults